DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hyoscyamine (Hyoscyamine Sulfate) - Summary

 
 



HYOSCYAMINE SUMMARY

Hyoscyamine Sulfate Extended-Release Tablets, USP contain 0.375 mg of hyoscyamine sulfate in a formulation designed for oral b. i. d dosage. Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids.

Hyoscyamine Sulfate Extended-Release Tablets, USP are effective as adjunctive therapy in the treatment of peptic ulcer. They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Hyoscyamine Sulfate Extended-Release Tablets, USP are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a "drying agent" in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.


See all Hyoscyamine indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Hyoscyamine

Sublingual hyoscyamine spray as premedication for colonoscopy: a randomized double-blinded placebo-controlled trial. [2008.07]
BACKGROUND: Colonic motility and spasm during colonoscopy may affect duration and quality of the examination as well as patient comfort during and after the procedure. Previous studies assessing the utility of antispasmodic agents in colonoscopy demonstrated conflicting results. The aim of this study was to determine the effect of sublingual hyoscyamine spray (IB-Stat, Inkine Pharmaceutical) on the performance of colonoscopy... CONCLUSIONS: Procedural difficulty and colonic motility scores were significantly lower in subjects who received sublingual hyoscyamine before colonoscopy.

Sublingual L-hyoscyamine for duodenal antimotility during ERCP: a prospective randomized double-blinded study. [2007.10]
BACKGROUND: ERCP is often made difficult by duodenal motility. Glucagon is typically used to inhibit this motility. L-hyoscyamine is an antimuscarinic, anticholinergic agent shown to be a feasible intravenous alternative to glucagon. OBJECTIVE: Demonstrate whether pre-ERCP sublingual L-hyoscyamine reduces the amount of glucagon required to complete ERCP... CONCLUSIONS: Preprocedure administration of sublingual L-hyoscyamine did not reduce the amount of glucagon required to complete ERCP.

more studies >>

Clinical Trials Related to Hyoscyamine

RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem [Recruiting]
The Trident Tritanium acetabular component of a total hip prosthesis is a new developed uncemented acetabular component. In this randomized controlled trial (RCT) the tritanium cup will be compared with the Trident HA acetabular component in two equal sized groups. The Symax HA coated stem will be used as femoral component in both groups.

Study Objectives:

- The primary objective is to determine the prosthetic migration of the uncemented

acetabular and femoral total hip components using model based RSA technique

- Secondary objectives are on one hand to assess clinical outcome on the other hand

assessing patient satisfaction in both groups using Harris Hip Score, Oxford Hip Score, WOMAC, and EQ-5D questionnaires

- Tertiary objective is to assess bone remodeling of the uncemented acetabular components

and the HA-coated Symax hip stem using QCT derived from usinf F18-fluoride PET in a cohort of 12 consecutive patients of this RCT

A total of 50 patients will be enrolled in this RCT divided into two equal groups. Patients have to fulfill the inclusion and exclusion criteria.

All evaluations will be done pre-operatively with 2 weeks before surgery, and after surgery at 4 weeks, 3 and 6 months and 1 and 2 years.

more trials >>

Reports of Suspected Hyoscyamine Side Effects

Completed Suicide (14)Herpes Zoster (4)Toxicity TO Various Agents (4)Vision Blurred (4)Arthritis (4)Renal Function Test Abnormal (2)Pain (2)Neoplasm Progression (2)Retinal Function Test Abnormal (2)Urinary Tract Disorder (2)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Hyoscyamine has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Hyoscyamine review by 29 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Irritable Bowel Syndrome
Dosage & duration:   1 0.375 mg tablet as needed taken 3-4 times a week for the period of 8 weeks
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   This medicine improved irritable bowel symptoms of cramping and constipation. No diarrhea was present before or during course of medicine.
Side effects:   There were no side effects other than slight drowsiness with the first few doses. After first few doses I didn't notice the drowsiness anymore.
Comments:   After suffering with worsening IBS symptoms of frequent bowel movements, cramping, and constipation for several years and trying dietary management of symptoms, the hyomax improved my symptoms to a manageable level with the first use.

See all Hyoscyamine reviews / ratings >>

Page last updated: 2008-08-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014